Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Tecentriq | Atezolizumab | Withdrawn | ||||
| Xospata | Gilteritinib | Reimburse with clinical criteria and/or conditions | Complete | |||
| Ibrance | Palbociclib | Withdrawn | ||||
| Latuda | lurasidone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Orilissa | elagolix | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Keytruda | Pembrolizumab | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Lynparza | Olaparib | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Avastin | Bevacizumab | Withdrawn | ||||
| Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024